Improving response to progestin treatment of low-grade endometrial cancer.

ABSTRACT:

Objectives

This review examines how response rates to progestin treatment of low-grade endometrial cancer can be improved. In addition to providing a brief overview of the pathogenesis of low-grade endometrial cancer, we discuss limitations in the current classification of endometrial cancer and how stratification may be refined using molecular markers to reproducibly identify 'low-risk' cancers which may represent the best candidates for progestin therapy. We also discuss constraints in current approaches to progestin treatment of low-grade endometrial cancer and perform a systematic review of predictive biomarkers.

Methods

PubMed, ClinicalTrials.gov, and Cochrane Library were searched for studies reporting pre-treatment biomarkers associated with outcome in women with low-

SUBMITTER: Baxter E 

PROVIDER: S-EPMC8445150 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature